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Aims Growth-differentiation factor-15 (GDF-15) has emerged as a biomarker of increased mortality and recurrent myo-
cardial infarction (MI) in patients diagnosed with non-ST-elevation acute coronary syndrome. We explored the use-
fulness of GDF-15 for early risk stratiﬁcation in 479 unselected patients with acute chest pain.
Methods
and results
Sixty-nine per cent of the patients presented with GDF-15 levels above the previously deﬁned upper reference limit
(1200 ng/L). The risks of the composite endpoint of death or (recurrent) MI after 6 months were 1.3, 5.1, and 12.6%
in patients with normal (,1200 ng/L), moderately elevated (1200–1800 ng/L), or markedly elevated (.1800 ng/L)
levels of GDF-15 on admission, respectively (P , 0.001). By multivariable analysis that included clinical characteristics,
ECGﬁndings,peakcardiactroponinIlevelswithin2 h(cTnI0–2 h),N-terminalpro-B-typenatriureticpeptide,C-reactive
protein, and cystatin C, GDF-15 remained an independent predictor of the composite endpoint. The ability of the
ECG combined with peak cTnI0–2 h to predict the composite endpoint was markedly improved by addition of
GDF-15 (c-statistic, 0.74 vs. 0.83; P , 0.001).
Conclusion GDF-15 improves risk stratiﬁcation in unselected patients with acute chest pain and provides prognostic information
beyond clinical characteristics, the ECG, and cTnI.
-----------------------------------------------------------------------------------------------------------------------------------------------------------
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Introduction
Rapid evaluation of patients with acute chest pain remains a
common challenge. The purpose of early triage is not only the
detection of acute myocardial infarction (MI), but also identiﬁ-
cation of other urgent conditions. In addition, stratiﬁcation con-
cerning the risk for subsequent adverse events is a main goal of
performed tests and procedures. The overall objective of early
triage is to allow targeting of patients at high risk to appropriate
levels and types of health care, including early implementation of
treatments known to reduce morbidity and mortality. Patients at
low risk also need early identiﬁcation to allow saving of resources
by early discharge and further evaluation in outpatient settings.
1,2
Apart from the patient’s history and physical ﬁndings, prognostic
assessment of patients with acute chest pain is based on ECG
registration and measurement of biomarkers of myocardial necro-
sis (e.g. the cardiac troponins) which, when abnormal, indicate an
increased risk of adverse events.
3–5
Growth-differentiation factor-15 (GDF-15) is a stress-responsive
member of the transforming growth factor-b cytokine superfamily.
In animal models, GDF-15 is induced in the heart in response to
ischaemia–reperfusion injury, pressure overload, and heart
failure, possibly via pro-inﬂammatory cytokine and oxidative stress-
dependent signalling pathways.
6,7 We have recently reported that
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associated with mortality, risk of recurrent MI, and the effects of
early invasive procedures in patients diagnosed with non-ST-
elevation acute coronary syndrome.
8,9
As these data were derived from highly selected, high-risk popu-
lations enrolled in clinical trials, the usefulness of GDF-15 for risk
stratiﬁcation needed to be evaluated in a heterogeneous, non-
selected, real-life patient cohort with chest pain. We therefore
assessed the circulating level of GDF-15 and its relation to clinical
risk indicators, other biomarkers, and outcome in patients with
acute chest pain from the FAST II (Fast Assessment of Thoracic
Pain) and FASTER I (Fast Assessment of Thoracic Pain by Neural
Networks) studies.
Methods
Study design
The present investigation is a substudy from the FAST II and FASTER I
trials in patients admitted to the coronary care unit with acute chest
pain. FAST II was conducted at Uppsala University Hospital between
May 2000 and March 2001.
10 The FASTER I trial included patients at
three centres in Sweden between October 2002 and August 2003.
11
Patients were eligible if admitted with chest pain suggestive of an
acute coronary syndrome and lasting for  15 min within the last
24 h (FAST II) or 8 h (FASTER I). In both studies, ST-segment elevation
in the admission 12-lead ECG leading to immediate reperfusion
therapy or its consideration was the only exclusion criterion. Blood
samples were obtained on admission, after 30–40 and 80–90 min
and after 2, 3, 6, and 12 h for immediate analysis of cardiac troponin
I (cTnI). In case of a clinical suspicion of an acute MI (FAST II) or
any cTnI elevation  0.1 mg/L within the ﬁrst 12 h (FASTER I), a last
cTnI measurement was obtained after 24 h. Additional EDTA plasma
samples obtained on admission were stored frozen in aliquots at
2708C for later determination of other biomarkers. All patients
received standard medical therapy; the need for revascularization
was determined by the treating physicians. Written informed
consent was obtained from all patients and the study protocol was
approved by the local Ethics Committees. For the present study,
169 patients from the FAST II trial and 310 patients from the
FASTER I trial with symptom onset within 8 h before admission, ﬁrst
time admission, and availability of plasma samples were included.
Laboratory analyses
The concentration of GDF-15 was determined by immunoradiometric
assay.
12 Patients were stratiﬁed based on two pre-speciﬁed GDF-15
cut-off levels, 1200 ng/L and 1800 ng/L. As previously shown, 1200 ng/L
corresponds to the upper limit of normal in apparently healthy,
elderly Swedish individuals.
12 In a previous study in patients with con-
ﬁrmed non-ST-elevation acute coronarysyndrome, 1200and1800 ng/L
corresponded to the lower and upper tertile boundaries and allowed
for an identiﬁcation of patients at low (,1200 ng/L), intermediate
(between 1200 and 1800 ng/L), or high risk (.1800 ng/L).
8
cTnI was analysed serially at the point of care using Stratus CS instru-
ments (DadeBehring, Deerﬁeld,IL, USA).FortheStratusCS cTnIassay,
the 99th percentile among healthy individuals is 0.07 mg/L, the lowest
concentration assuring an analytical imprecision (CV) of ,10% is
0.1 mg/L.
13 N-terminal pro-B-type natriuretic peptide (NT-proBNP)
wasdeterminedwithasandwichimmunoassayonanElecsys2010instru-
ment (RocheDiagnostics,Mannheim,Germany).C-reactiveproteinwas
analysedwithachemiluminescentenzyme-labelledimmunometricassay
on an Immulite 1000 analyser (Diagnostic Products Corp., Los Angeles,
CA,USA). CystatinCwasmeasuredusinga latex-enhanced reagent and
a BN ProSpec analyser (Dade Behring).
ECG analysis
A resting 12-lead ECG was obtained on admission and interpreted by
an independent investigator unaware of the patient’s clinical outcome.
ST-segment depression was deﬁned as a downward deviation of the
ST-segment of  0.05 mV below the isoelectric line in any lead.
T-wave inversion was considered present when a negative or isoelec-
tric T-wave was found in leads I, II, or V2–V6, in lead aVL if the ampli-
tude of the R-wave was .0.5 mV, or in lead aVF if the QRS-amplitude
was mainly positive. Patients without sinus rhythm, with pathological
Q-waves (duration .0.03 s and an amplitude .25% of the following
R-wave amplitude), left bundle branch block, ST-segment depression,
or T-wave inversion were regarded as having an abnormal ECG.
Deﬁnition of the index diagnosis
Index events were classiﬁed by independent investigators with access
to all clinical and laboratory data but unaware of the patients’ clinical
outcome. Acute MI was diagnosed in accordance with the ESC/ACC
consensus document, using cTnI elevation  0.1 mg/L in at least two
measurements within 24 h from admission as the biochemical
criterion.
14
Follow-up
After discharge, patients were followed by research nurses with tele-
phone contacts at 30 days and at 6 (+1) months. Information regarding
death was obtained from the Swedish National Registry on Mortality,
informationregarding (recurrent) MI from the hospitals’ diagnosis regis-
try and patient records. No patient was lost to follow-up.
Statistical analysis
Continuous variables are reported as medians (interquartile range);
comparisons were performed by the Mann–Whitney U test or the
Kruskal–Wallis test, as appropriate. Categorical variables are
expressed as numbers and percentages, differences were analysed
using Pearson’s x
2 test. To evaluate the relationships between continu-
ous variables, Spearman’s rank-correlation coefﬁcients were calcu-
lated. To evaluate the associations between GDF-15 levels and
clinical baseline variables (age, gender, hypertension, diabetes, hyperli-
pidaemia, previous or current smoking, history of coronary revascular-
ization, previous MI, heart failure, abnormal admission ECG) and
biomarker results [peak levels of cTnI  0.1 mg/L within 2 h
(cTnI0–2 h), NT-proBNP, C-reactive protein, and cystatin C], multiple
linear regression analysis was used. Because of the signiﬁcant pro-
portion of patients with undetectable levels of cTnI, this marker was
entered into the analysis as a dichotomized variable on the basis of
cTnI0–2 h , or  0.1 mg/L. The other biomarkers were entered as
continuous variables, in case of NT-proBNP, C-reactive protein, and
GDF-15 after ln transformation due to highly skewed levels.
The study endpoints were total mortality and (recurrent) MI, alone
or in combination. To compare the prognostic information provided
by different biochemical markers, receiver operator characteristic
(ROC) curves were generated. Differences between the areas under
the ROC curves were assessed using the Wilcoxon one-sample test.
The prognostic importance of GDF-15 and the clinical risk indicators
and biochemical markers included in the multiple linear regression
analysis was assessed by logistic regression analysis using univariable
and multivariable models. The multivariable model included all
tested variables. In addition, the prognostic value of the pre-speciﬁed
K.M. Eggers et al. 2328GDF-15 cut-off levels of 1200 ng/L and 1800 ng/L was tested alone and
in combination with peak cTnI0–2hor an abnormal ECG on admission.
All P-values reported are from two-sided tests and regarded as statisti-
cally signiﬁcant if ,0.05. No adjustments for multiplicity were made as
the results are to be considered exploratory. All data analyses were
performed using the Statistical Package for Social Sciences 12.0.1 and
14.0 software programs (SPSS Inc., Chicago, IL, USA).
Results
Patient characteristics
The combined patient cohort consisted of 479 patients (65%
males) with a median (inter-quartile range) age of 66 (57–75)
years. The median time from symptom onset to admission and
ﬁrst blood sample was 4.9 (3.4–6.9) h. The index event was classi-
ﬁed as an acute MI in 144 patients (30%), unstable angina in 84
patients (18%), other cardiac disease in 52 patients (11%), non-
cardiac disease in 31 patients (6%), and unspeciﬁed chest pain in
168 patients (35%). The group with other cardiac disease included
patients with stable angina, arrhythmias, or manifestations of
chronic heart failure, the group with non-cardiac disease included
patients with gastrointestinal disorders, pulmonary, or aortic
disease. Baseline characteristics are summarized in Table 1.
Growth-differentiation factor-15 levels on
admission in relation to baseline variables
The concentration of GDF-15 on admission ranged from 50 to
24 850 ng/L, with a median (inter-quartile range) of 1496 (1101–
2279) ng/L. One hundred and forty-nine patients (31%) presented
with a GDF-15 level within the normal range (,1200 ng/L).
GDF-15 levels were moderately elevated (between 1200 and
1800 ng/L) in 156 patients (33%) and highly elevated (.1800 ng/L)
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Table 1 Clinical characteristics
FAST II (n 5 169) FASTER I (n 5 310) Combined (n 5 479)
Demographics
Age (years) 67 (58–75) 65 (57–76) 66 (57–75)
Male gender 112 (66) 200 (65) 312 (65)
Cardiovascular risk factors
Hypertension 80 (47) 119 (38) 199 (42)
Diabetes 27 (16) 53 (17) 80 (17)
Hyperlipidaemia 47 (28) 123 (40) 170 (35)
Previous or current smoking 101 (60) 186 (60) 287 (60)
Previous cardiovascular disease
Angina pectoris .1 month 77 (46) 124 (40) 201 (42)
Previous revascularization 50 (30) 89 (29) 139 (29)
Previous MI 65 (38) 97 (31) 162 (34)
Heart failure 31 (18) 47 (15) 78 (16)
ECG on admission
ST-segment depression 22 (16) 54 (21) 76 (19)
T-wave inversion 42 (30) 46 (18) 88 (22)
LBBB 9 (5) 12 (4) 21 (4)
Q-wave 22 (13) 37 (12) 59 (12)
Any abnormal ECG 93 (55) 149 (48) 242 (51)
Biomarker levels
cTnI  0.1 mg/L within 2 h 59 (35) 102 (33) 161 (34)
NT-proBNP (ng/L) 222 (86–836) 174 (62–655) 190 (75–740)
C-reactive protein (mg/L) 1.87 (0.91–4.65) 2.35 (1.29–5.62) 2.09 (0.98–4.93)
Cystatin C (mg/L) 1.07 (0.94–1.27) 1.18 (1.08–1.33) 1.15 (1.03–1.32)
Index diagnosis
Acute MI 44 (26) 100 (32) 144 (30)
Unstable angina 21 (12) 63 (20) 84 (18)
Other cardiac disease 40 (24) 12 (4) 52 (11)
Non-cardiac disease 17 (10) 14 (5) 31 (6)
Unspeciﬁed chest pain 47 (28) 121 (39) 168 (35)
Data are presented as absolute number (percentage) or median (inter-quartile range). Analysis of ST-segment changes was based on 402 patients without confounding ECG
ﬁndings, i.e. left bundle branch block (LBBB) or pacing.
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tended to be older and were more likely to have hypertension
or diabetes, to have a history of tobacco use or cardiovascular
disease, or to present with an abnormal ECG (Table 2). Patients
with elevated levels of GDF-15 were also more likely to develop
a peak cTnI0–2 h level  0.1 mg/L or to present with increased
levels of NT-proBNP, C-reactive protein, or cystatin C (Table 2).
The relation of GDF-15 to these four biomarkers was further illus-
trated by linear correlation analysis, showing that GDF-15 levels
were strongly related to cystatin C (r ¼ 0.59; P , 0.001) and
NT-proBNP (r ¼ 0.58; P , 0.001) and weakly related to
C-reactive protein (r ¼ 0.27; P , 0.001) and peak cTnI0–2h
(r ¼ 0.22; P , 0.001).
By multiple linear regression analysis using ln GDF-15 as the
dependent variable, age, male gender, diabetes, a history of
smoking, and the levels of NT-proBNP, C-reactive protein, and
cystatin C were signiﬁcantly related to GDF-15 (Table 3). The R
2
value of this model was 0.60.
Growth-differentiation factor-15 levels
on admission in relation to diagnosis
The median (inter-quartile range) GDF-15 level in patients with a
ﬁnal diagnosis of acute MI was 1701 (1312–2684) ng/L, 1452
(1208–2218) ng/L in patients with unstable angina, 1805 (1307–
2591) ng/L in patients with other cardiac disease, and 1628
(1157–2366) ng/L in patients with non-cardiac disease. The
median GDF-15 level in patients with unspeciﬁed chest pain was
1207 (891–1737) ng/L, which was signiﬁcantly lower when com-
pared with patients with other index diagnoses (P , 0.005).
Patients with unspeciﬁed chest pain were signiﬁcantly younger,
had less-established cardiovascular disease, and had lower levels
of NT-proBNP, C-reactive protein, and cystatin C when compared
with the other diagnostic subgroups (data not shown). Distribution
of GDF-15 levels according to index diagnosis and the pre-
speciﬁed cut-off values of 1200 and 1800 ng/L is shown in
Figure 1. Among patients with a ﬁnal diagnosis of acute MI, 83%
presented with elevated levels of GDF-15 ( 1200 ng/L); the
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Table 2 Baseline characteristics according to growth-differentiation factor-15 levels on admission
GDF-15 <1200 ng/L
(n 5 149)
GDF-15 1200–1800 ng/L
(n 5 156)
GDF-15 >1800 ng/L
(n 5 174)
P-value
Demographics
Age (years) 56 (50–63) 67 (60–74) 75 (65–80) ,0.001
Male gender 92 (62) 102 (65) 118 (68) 0.52
Delay time (h) 4.8 (3.6–6.8) 5.1 (3.5–6.6) 4.8 (3.1–6.9) 0.61
Cardiovascular risk factors
Hypertension 47 (32) 59 (38) 93 (53) ,0.001
Diabetes 9 (6) 20 (13) 51 (29) ,0.001
Hyperlipidaemia 46 (31) 50 (32) 74 (43) 0.05
Previous or current
smoking
72 (48) 103 (66) 112 (64) 0.002
Previous cardiovascular disease
Angina pectoris .1 month 39 (26) 57 (37) 105 (60) ,0.001
Previous revascularization 32 (22) 38 (24) 69 (40) ,0.001
Previous MI 32 (21) 41 (26) 89 (51) ,0.001
Heart failure 5 (3) 17 (11) 56 (32) ,0.001
ECG on admission
ST-segment depression 12 (9) 24 (18) 40 (32) ,0.001
T-wave inversion 19 (14) 36 (26) 33 (26) 0.01
LBBB 3 (2) 2 (1) 16 (9) 0.001
Q-wave 11 (7) 19 (12) 29 (17) 0.04
Any abnormal ECG 44 (30) 76 (49) 122 (70) ,0.001
Biomarker levels
cTnI  0.1 mg/L within 2 h 32 (21) 59 (38) 70 (40) 0.001
NT-proBNP (ng/L) 74 (29–165) 177 (99–493) 728 (199–1871) ,0.001
C-reactive protein (mg/L) 1.47 (0.79–3.10) 2.00 (1.01–4.04) 3.25 (1.33–9.19) ,0.001
Cystatin C (mg/L) 1.04 (0.95–1.12) 1.16 (1.06–1.26) 1.36 (1.16–1.59) ,0.001
Data are presented as absolute number (percentage) or median (inter-quartile range). Analysis of ST-segment changes was based on 402 patients without confounding ECG
ﬁndings, i.e. left bundle branch block (LBBB) or pacing. Delay time refers to the time from symptom onset to ﬁrst blood sample.
K.M. Eggers et al. 2330respective numbers were 76, 79, 71, and 50% in patients with
unstable angina, other cardiac disease, non-cardiac disease, and
unspeciﬁed chest pain, respectively.
Growth-differentiation factor-15 levels
on admission in relation to outcome
After 6 months, 13 patients (2.7%) had died and 23 patients (4.8%)
had suffered a (recurrent) MI. Overall, 32 patients (6.7%) had
reached the composite endpoint of death or (recurrent) MI. The
risk of the composite endpoint was 14.6% (21 out of 144 patients)
among patients with an index diagnosis of acute MI, 6.0% (ﬁve out
of 84) among patients with unstable angina, 7.7% (four out of 52)
among patients with other cardiac disease, and 6.5% (2 out of 31)
among patients with non-cardiac disease. No patient with unspeci-
ﬁed chest pain reached the composite endpoint.
There was a graded relationship between the levels of
GDF-15 on admission and the risk of death and/or (recurrent)
MI during follow-up (Figure 2A). No deaths occurred among
patients with GDF-15 levels ,1200 ng/L, whereas two patients
(1.3%) with GDF-15 levels between 1200 and 1800 ng/L and
11 patients (6.3%) with GDF-15 levels .1800 ng/L died (P ¼
0.001). Likewise, two (1.3%), seven (4.5%), and 14 (8.0%)
patients had a (recurrent) MI (P ¼ 0.019), and two (1.3%),
eight (5.1%) and 22 (12.6%) patients reached the composite
endpoint in the three strata of GDF-15 (P , 0.001). The
timing of events for the composite endpoint in shown in
Figure 2B. Patients who reached the composite endpoint had sig-
niﬁcantly higher median (inter-quartile range) levels of GDF-15
on admission [2904 (1701–4159) ng/L] when compared with
patients without an event [1462 (1077–2083) ng/L; P , 0.001].
GDF-15 levels were also signiﬁcantly higher in patients who
died during follow-up [4139 (2663–5088) ng/L] when compared
with patients who survived [1479 (1090–2191) ng/L; P , 0.001]
and in patients who had a (recurrent) MI [2583 (1614–
3468) ng/L] when compared with patients without such event
[1476 (1084–2205) ng/L; P ¼ 0.001].
Growth-differentiation factor-15 in the
context of other markers of adverse
prognosis
By univariable logistic regression analysis, age, a history of previous
MI, abnormal ECG ﬁndings, a peak cTnI0–2 h level  0.1 mg/L, and
the levels of NT-proBNP, C-reactive protein, cystatin C, and
GDF-15 were all related to the risk of the composite endpoint
after 6 months (Table 4). ROC curve analysis further illustrated
Figure 1 Levels of growth-differentiation factor-15 on admission in relation to index diagnosis. For each diagnosis, the percentages of patients
with growth-differentiation factor-15 levels ,1200 ng/L, between 1200 and 1800 ng/L, and .1800 ng/L are shown. Absolute patient numbers
are shown in each bar.
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Table 3 Clinical and biochemical variables associated
with growth-differentiation factor-15
Characteristics B (95% CI) P-value
Age (per 10 years) 0.12 (0.09–0.16) ,0.001
Male gender 0.11 (0.04–0.19) 0.002
Hypertension 0.01 (20.06 to 0.09) 0.73
Diabetes 0.36 (0.26–0.46) ,0.001
Hyperlipidaemia 0.03 (20.06 to 0.12) 0.49
Previous or current smoking 0.10 (0.03–0.17) 0.005
Previous revascularization 20.07 (20.17 to 0.03) 0.15
Previous MI 0.04 (20.05 to 0.13) 0.36
Previous heart failure 0.06 (20.05 to 0.16) 0.28
Any abnormal ECG 20.04 (20.11 to 0.04) 0.37
cTnI  0.1 mg/L within 2 h 20.07 (20.14 to 0.01) 0.08
ln NT-proBNP 0.08 (0.05–0.11) ,0.001
ln C-reactive protein 0.06 (0.03–0.09) ,0.001
Cystatin C 0.65 (0.52–0.76) ,0.001
Trial (FAST II vs. FASTER I) 0.03 (20.04 to 0.10) 0.41
Multiple linear regression analysis. Association with ln GDF-15 is shown. CI
denotes conﬁdence interval.
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endpoint with a c-statistic of 0.78 (optimal cut-off, 2170 ng/L),
when compared with cystatin C (c-statistic, 0.76), NT-proBNP
(c-statistic, 0.75), peak cTnI0–2 h (c-statistic, 0.73), and C-reactive
protein (c-statistic, 0.61).
By multivariable analysis, a peak cTnI0–2 hlevel  0.1 mg/L [odds
ratio (OR), 4.7; 95% conﬁdence interval (CI) 1.8–12.0; P ¼ 0.001)
and GDF-15 (OR, 2.7; 95% CI 1.0–6.9; P ¼ 0.046) emerged as the
only independent predictors of the composite endpoint (Table 4).
Removing cystatin C from the model improved the predictive value
of GDF-15 (OR, 3.6; 95% CI 1.5–8.4; P ¼ 0.003), whereas the
prognostic value of cTnI0–2 h  0.1 mg/L remained unchanged
(OR 4.5; 95% CI 1.8–11.4; P ¼ 0.002).
A single value of GDF-15 within the normal range (,1200 ng/L)
on admission performed better in identifying low-risk patients,
than a peak cTnI0–2 h level ,0.1 mg/L: among patients with a
normal GDF-15 level, 1.3% (two out of 149) reached the
composite endpoint after 6 months, whereas 2.9% (nine out of
312) of the patients with a peak cTnI0–2h level ,0.1 mg/L did
(P ¼ 0.039).
Growth-differentiation factor-15 adds
prognostic information to the ECG and
cardiac troponin I
GDF-15 levels determined on admission added signiﬁcant prognos-
tic information to ECG ﬁndings on admission and peak cTnI0–2 h
levels. This was reﬂected by an increase in the c-statistic for the
composite endpoint from 0.74 (95% CI 0.65–0.83) for the combi-
nation of peak cTnI0–2 hand the ECG to 0.83 (95% CI 0.76–0.90)
after addition of GDF-15 (P , 0.001). Among patients with an
abnormal ECG or with peak cTnI0–2h levels  0.1 mg/L, a
GDF-15 level within the normal range (,1200 ng/L) identiﬁed
individuals at very low risk of adverse events: none out of 44
Figure 2 Outcome according to levels of growth-differentiation factor-15 on admission. (A) The risks of death, (recurrent) MI, and of the
composite endpoint after 6 months are shown. The number of events is shown in each bar. (B) The Kaplan–Meier curve illustrating the
timing of events for the composite endpoint in the three strata of growth-differentiation factor-15. (Re)-MI denotes (recurrent) myocardial
infarction.
K.M. Eggers et al. 2332patients with an abnormal ECG but a normal GDF-15 value
reached the composite endpoint after 6 months; similarly, there
was only one event among 32 patients with a peak cTnI0–2 h
level  0.1 mg/L and normal GDF-15 value (Figure 3A). Conversely,
in patients with peak cTnI0–2 hlevels ,0.1 mg/L or a normal ECG,
a GDF-15 level .1800 ng/L offered incremental prognostic infor-
mation and identiﬁed individuals at high risk of the composite
endpoint (Figure 3B).
................................................ ................................................
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Table 4 Logistic regression analyses for the composite endpoint at 6 months in relation to risk markers at presentation
Univariable model Multivariable model
Characteristics OR (95% CI) P-value OR (95% CI) P-value
Age (per 10 years) 2.2 (1.5–3.2) ,0.001 1.1 (0.7–1.7) 0.82
Male gender 1.4 (0.6–3.1) 0.40 1.0 (0.4–2.7) 0.96
Hypertension 1.3 (0.6–2.6) 0.54 1.0 (0.4–2.5) 0.94
Diabetes 1.4 (0.6–3.6) 0.46 0.7 (0.2–2.0) 0.46
Hyperlipidaemia 0.6 (0.3–1.3) 0.21 0.4 (0.1–1.3) 0.12
Previous or current smoking 0.7 (0.4–1.5) 0.41 0.6 (0.2–1.3) 0.17
Previous revascularization 1.3 (0.6–2.8) 0.49 1.5 (0.5–4.5) 0.44
Previous MI 2.7 (1.3–5.6) 0.007 2.1 (0.8–5.4) 0.14
Previous heart failure 2.1 (0.9–4.8) 0.07 0.6 (0.2–1.8) 0.39
Any abnormal ECG 3.1 (1.4–7.0) 0.007 1.2 (0.4–3.2) 0.77
cTnI  0.1 mg/L within 2 h 5.7 (2.5–12.5) ,0.001 4.7 (1.8–12.0) 0.001
ln NT-proBNP 1.8 (1.4–2.3) ,0.001 1.0 (0.7–1.5) 0.84
ln C-reactive protein 1.4 (1.1–1.8) 0.013 1.2 (0.9–1.7) 0.29
Cystatin C 9.0 (3.4–23.6) ,0.001 2.7 (0.7–10.4) 0.16
ln GDF-15 4.5 (2.5–8.1) ,0.001 2.7 (1.0–6.0) 0.046
OR, odds ratio; CI, conﬁdence interval. The multivariable model was adjusted for all variables in the univariable model and for trial (FAST II vs. FASTER I).
Figure 3 Outcome according to the ECG, peak cTnI levels within 2 h, and growth-differentiation factor-15. Patients were stratiﬁed according
to the presence or absence of an abnormal ECG on admission or according to their peak cTnI0–2 h level (cTnI). Patients were then classiﬁed
according to their levels of growth-differentiation factor-15 on admission using the pre-speciﬁed cut-offs, 1200 ng/L (A) and 1800 ng/L (B). The
number of events per number of patients is shown in each bar.
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This study shows that the level of GDF-15, as measured in the ﬁrst
blood sample on admission, provides independent prognostic
information on the risk of death or (recurrent) MI in a hetero-
geneous patient population with acute chest pain. Patients with a
GDF-15 level within the normal range (,1200 ng/L) had a very
good prognosis with a 6-month risk of the composite endpoint
of 1.3% without any deaths. Conversely, the prognosis was signiﬁ-
cantly impaired at higher GDF-15 levels, with rates of the compo-
site endpoint of 5.1 and 12.6% in patients with moderately elevated
(between 1200 and 1800 ng/L) or markedly elevated (.1800 ng/L)
levels of GDF-15, respectively.
Currently, serial analyses of the ECG and troponin testing are
the recommended procedures for triage and early risk stratiﬁca-
tion in patients with chest pain suggestive of an acute coronary syn-
drome.
1,2 The presence of an abnormal ECG or elevated levels of
troponin is associated with an increased risk of adverse cardiac
events in patients with conﬁrmed non-ST-elevation acute coronary
syndrome,
15–17 and in more unselected chest pain populations.
3–5
However, in unselected populations, a signiﬁcant proportion of
patients with a ﬁnal diagnosis of non-cardiac disease, or even
unspeciﬁed chest pain, may have elevated levels of cTnI.
18 More-
over, some patients with acute chest pain and elevated levels of
cTnI do not have blood ﬂow-limiting coronary artery disease,
5
highlighting the need for additional markers to identify individuals
at high risk of adverse cardiac events among the heterogeneous
group of troponin-positive patients.
GDF-15, measured onadmission,addedprognosticinformationto
theECGandtocTnImeasuredseriallyduringtheﬁrst2 hfromadmis-
sion. A GDF-15 level ,1200 ng/L identiﬁed low-risk subjects among
the patient cohorts with an abnormal ECG or elevated cTnI. In con-
trast, a GDF-15 level .1800 ng/L was useful for the identiﬁcation of
high-risk individuals among the cohorts with a normal ECG or
without elevated cTnI, which are usually regarded as low-risk. Given
the complexity of cardiac risk modelling, these results have to be
regarded as explorative. Although our data indicate that 1200 and
1800 ng/L are useful cut-points for risk stratiﬁcation, this does not
imply that risk is homogeneous within each of these strata.
It has been shown that a multimarker strategy combining the
ECG and markers of myocyte necrosis with markers of renal dys-
function, inﬂammation, or natriuretic peptides may provide
additional insight into pathophysiological mechanisms and
enhance risk stratiﬁcation in patients with chest pain and unstable
coronary artery disease.
19–21 Elevated levels of NT-proBNP,
C-reactive protein, cystatin C, and GDF-15 were all related to a
higher risk of adverse outcomes in the present study. Among
these biomarkers, only GDF-15 provided independent prognostic
information besides cTnI in our patient population. It thus
appears that GDF-15 could provide incremental prognostic infor-
mation even to more complex risk prediction models. This,
however, remains to be validated prospectively.
Patients presenting with elevated GDF-15 levels were character-
ized by high-risk features such as increased age and a higher preva-
lence of cardiovascular risk factors and previous cardiovascular
disease. In accordance with previous experiences,
8,9,22 age, male
gender, diabetes, smoking, ventricular wall stress and ischaemia
(NT-proBNP), inﬂammation (C-reactive protein), and renal dys-
function (cystatin C) were independently associated with elevated
GDF-15 levels. Thus, an elevated level of GDF-15 seems to reﬂect
several underlying conditions, acute and/or chronic, associated
with adverse cardiovascular outcomes. In particular, renal dysfunc-
tion appeared to mediate part of the prognostic impact of GDF-15
given the close correlation between levels of GDF-15 and cystatin
C and considering the results of the multivariable analysis.
However, the aforementioned factors explained only part of the
variation in the GDF-15 levels, indicating that additional, as yet
undeﬁned factors contribute to the concentration of GDF-15.
GDF-15 is highly expressed in the infarcted myocardium in patients
with an acute MI,
6 and also in atherosclerotic plaques obtained
from patients undergoing carotid artery surgery.
23 It will be
important to further elucidate the factors regulating the expression
GDF-15 in the myocardium and in the vessel wall to improve the
understanding of the pathobiology of this new biomarker.
Patients with unspeciﬁed chest pain presented with signiﬁcantly
lower GDF-15 levels when compared with the other diagnostic
subgroups, which seems related to the fact that these individuals
were younger and had less-established cardiovascular disease and
no acute cardiac condition. Otherwise, there was a considerable
overlap in the GDF-15 levels in patients with different chest pain
aetiologies. As previously shown, circulating levels of GDF-15 are
elevated and provide independent prognostic information in
patients with unstable angina and non-ST-elevation MI,
8
ST-elevation MI,
24 chronic ischaemic and non-ischaemic heart
failure,
22 and acute pulmonary embolism,
25 indicating that elevated
GDF-15 levels identify high-risk individuals across a broad spec-
trum of cardiovascular disease. Conversely, GDF-15 levels
,1200 ng/L have been found to be associated with favourable out-
comes in all of these conditions. Accordingly, the role of GDF-15
in the differential diagnostic work-up of patients with acute chest
pain may be limited. Instead, GDF-15 may be useful for risk strati-
ﬁcation at initial presentation across the heterogeneous spectrum
of patients with acute chest pain.
In conclusion, GDF-15 is a strong and independent biomarker of
adverse outcome in patients with acute chest pain. GDF-15 pro-
vides prognostic information beyond conventional risk markers,
such as the ECG and serial cTnI measurements. Recent data
suggest that patients with non-ST-elevation acute coronary syn-
drome presenting with an elevated GDF-15 level beneﬁt from
early revascularization, whereas patients with a normal GDF-15
level do not, regardless of their troponin levels.
9 Accordingly,
GDF-15 may be valuable for early triage and therapeutic decision-
making. The impact on resource utilization, health-care costs, and
patient outcome of a management strategy that incorporates
GDF-15 should be explored in a prospective clinical trial.
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